The Journal of Korean Medicine (대한한의학회지)

The Society of Korean Medicine (대한한의학회)
권호 표지

A Case of Non-alcoholic Steatohepatitis Treated with Herbal Medicine

  • Son, Chang-Gue (Liver and Immunology Research Center, Oriental Medical College in Daejeon University)
  • Received : 2011.03.29
  • Accepted : 2011.05.04
  • Published : 2011.05.30
Download PDF
⟨ Previous Next ⟩

Abstract

Objective: To understand the characteristic of non-alcoholic fatty liver disease (NAFLD) and non-alcoholic steatohepatitis (NASH), and study the traditional Korean medicine (TKM)-based strategies or therapeutics for them. Methods: A male patient with NASH was treated with only Oriental therapies, and then the clinical outcome was evaluated by serum biochemical parameters and radiographs. Result: The clinical and biochemical values of the patient fluctuated over three years according to the treatments and cessation of herbal medicines. Conclusion: NASH or NAFLD are now prevalent and these disorders could be targets of TKM, and this case report would provide useful information.

Keywords

References

  1. Adams LA, Angulo P. Treatment of nonalcoholic fatty liver disease. Postgrad Med J. 2006; 82(967):315-22. https://doi.org/10.1136/pgmj.2005.042200
  2. Farrell GC, Chitturi S, Lau GK, Sollano JD. Guidelines for the assessment and management of non-alcoholic fatty liver disease in the Asia-Pacific region: executive summary. J Gastroenterol Hepatol. 2007; 22(6):775-7. https://doi.org/10.1111/j.1440-1746.2007.05002.x
  3. Clark JM, Diehl AM. Nonalcoholic fatty liver disease: an underrecognized cause of cryptogenic cirrhosis. JAMA, 2003; 289 (22): 3000-4. https://doi.org/10.1001/jama.289.22.3000
  4. Chavez-Tapia NN, Uribe M, Ponciano- Rodríguez G, Medina-Santillán R, Méndez- Sánchez N. New insights into the pathophysiology of nonalcoholic fatty liver disease. Ann Hepatol. 2009; 8:S9-S17.
  5. Abrams GA, Kunde SS, Lazenby AJ, Clements RH. Portal fibrosis and hepatic steatosis in morbidly obese subjects: a spectrum of nonalcoholic fatty liver disease. Hepatology. 2004; 40:475-83. https://doi.org/10.1002/hep.20323
  6. Neuschwander-Tetri BA. Lifestyle modification as the primary treatment of NASH. Clin Liver Dis. 2009; 13(4):649-65. https://doi.org/10.1016/j.cld.2009.07.006
  7. Larter CZ, Chitturi S, Heydet D, Farrell GC. A fresh look at NASH pathogenesis. Part 1: the metabolic movers. J Gastroenterol Hepatol. 2010 Apr; 25(4):672-90. https://doi.org/10.1111/j.1440-1746.2010.06253.x
  8. Golovanova EV, Vinnitskaia EV, Shaposhnikova NA, Petrakov AV, Mel'kina ES. Effectiveness of the new plant hepatoprotector--Ropren in patients with non-alcoholic steatohepatitis. Eksp Klin Gastroenterol. 2010; (7):97-102.
  9. Jaeschke H, Williams CD, McGill MR, Farhood A. Herbal extracts as hepatoprotectants against acetaminophen hepatotoxicity. World J Gastroenterol. 2010; 16(19):2448-50. https://doi.org/10.3748/wjg.v16.i19.2448
  10. Chien CF, Wu YT, Tsai TH. Biological analysis of herbal medicines used for the treatment of liver diseases. Biomed Chromatogr. 2011; 25(1-2):21-38. https://doi.org/10.1002/bmc.1568
  11. Acikel M, Sunay S, Koplay M, Gundogdu F, Karakelleoglu S. Evaluation of ultrasonographic fatty liver and severity of coronary atherosclerosis, and obesity in patients undergoing coronary angiography. Anadolu Kardiyol Derg. 2009; 9(4):273-9.
  12. Newton JL, Pairman J, Wilton K, Jones DE, Day C. Fatigue and autonomic dysfunction in non-alcoholic fatty liver disease. Clin Auton Res. 2009; 19(6):319-26. https://doi.org/10.1007/s10286-009-0031-4
  13. Alazmi WM, Regev A, Molina EG, Schiff ER. Predictors of cirrhosis in Hispanic patients with nonalcoholic steatohepatitis. Dig Dis Sci. 2006; 51(10):1725-9. https://doi.org/10.1007/s10620-005-9065-1
  14. Powell EE, Cooksley WG, Hanson R, Searle J, Halliday JW, Powell LW. The natural history of nonalcoholic steatohepatitis: a follow-up study of forty-two patients for up to 21 years. Hepatology. 1990; 11(1):74-80. https://doi.org/10.1002/hep.1840110114
  15. Adams LA, Feldstein AE. Nonalcoholic steatohepatitis: risk factors and diagnosis. Expert Rev Gastroenterol Hepatol. 2010; 4(5):623-35. https://doi.org/10.1586/egh.10.56
  16. Marchesini G, Marzocchi R. Metabolic syndrome and NASH. Clin Liver Dis. 2007; 11(1):105-17. https://doi.org/10.1016/j.cld.2007.02.013
  17. Tsochatzis EA, Papatheodoridis GV. Smoking is associated with histological severity in nonalcoholic steatohepatitis. Hepatology. 2010; 52(4):1522-3. https://doi.org/10.1002/hep.23751
  18. Videla LA, Rodrigo R, Araya J, Poniachik J. Insulin resistance and oxidative stress interdependency in non-alcoholic fatty liver disease. Trends Mol Med. 2006; 12(12):555-8. https://doi.org/10.1016/j.molmed.2006.10.001
  19. Petersen KF, Dufour S, Hariri A, Nelson- Williams C, Foo JN, Zhang XM, et al. Apolipoprotein C3 gene variants in nonalcoholic fatty liver disease. N Engl J Med. 2010; 362(12):1082-9. https://doi.org/10.1056/NEJMoa0907295
  20. Carulli L, Canedi I, Rondinella S, Lombardini S, Ganazzi D, Fargion S, et al. Genetic polymorphisms in non-alcoholic fatty liver disease: interleukin-6-174G/C polymorphism is associated with non-alcoholic steatohepatitis. Dig Liver Dis. 2009; 41(11):823-8. https://doi.org/10.1016/j.dld.2009.03.005
  21. Malinska H, Oliyarnyk O, Hubova M, Zidek V, Landa V, Simakova M, et al. Increased liver oxidative stress and altered PUFA metabolism precede development of non-alcoholic steatohepatitis in SREBP-1a transgenic spontaneously hypertensive rats with genetic predisposition to hepatic steatosis. Mol Cell Biochem. 2010; 335(1-2): 119-25. https://doi.org/10.1007/s11010-009-0248-5
  22. Caldwell S, Lazo M. Is exercise an effective treatment for NASH? Knowns and unknowns. Ann Hepatol. 2009; 8 Suppl 1:S60-6.
  23. Haddad Y, Vallerand D, Brault A, Haddad PS. Antioxidant and Hepatoprotective Effects of Silibinin in a Rat Model of Nonalcoholic Steatohepatitis. Evid Based Complement Alternat Med. 2009. Epub ahead of print.
  24. Kim SH, Lee JH, Jung YJ, Choi MY, Kim YC, Woo HJ. A Case of Nonalcoholic Steatohepatitis in a child patient. Korean J. Orient. Int. 2010; 31(2):1106-10.
  25. Hu XP, Shin JW, Wang JH, Cho JH, Son JY, Cho CK, et al. Antioxidative and hepatoprotective effect of CGX, an herbal medicine, against toxic acute injury in mice. J Ethnopharmacol. 2008; 120(1):51-5. https://doi.org/10.1016/j.jep.2008.07.042
  26. Wang JH, Shin JW, Son JY, Cho JH, Son CG. Antifibrotic effects of CGX, a traditional herbal formula, and its mechanisms in rats. J Ethnopharmacol. 2010; 127(2):534-42. https://doi.org/10.1016/j.jep.2009.10.001